The Growing Epidemic of HPV-Positive Oropharyngeal Carcinoma: A Clinical Review for Primary Care Providers

References

1. 1.↵
   1. Pytynia KB,
   2. Dahlstrom KR,
   3. Sturgis EM

   . Epidemiology of HPV-associated oropharygeal cancer. Oral Oncol 2014;50:380–6.

   OpenUrlCrossRefPubMedWeb of Science
2. 2.↵
   1. Mehanna H,
   2. Beech T,
   3. Nicholson T,
   4. et al

   . Prevalence of human papillomavirus in oropharyngeal and nonoropharyngeal head and neck cancer—systematic review and meta-analysis of trends by time and region. Head Neck 2013;35:747–55.

   OpenUrlCrossRefPubMed
3. 3.↵
   1. Chaturvedi AK,
   2. Engels EA,
   3. Pfeiffer RM,
   4. et al

   . Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 2011;29:4294–301.

   OpenUrlAbstract/FREE Full Text
4. 4.↵
   1. McIlwain WR,
   2. Sood AJ,
   3. Nguyen SA,
   4. Day TA

   . Initial symptoms in patients with HPV-positive and HPV-negative oropharyngeal cancer. JAMA Otolaryngol Head Neck Surg 2014;140:441–7.

   OpenUrlCrossRefPubMed
5. 5.↵
   1. O'Rorke MA,
   2. Ellison MV,
   3. Murray LJ,
   4. Moran M,
   5. James J,
   6. Anderson LA

   . Human papillomavirus related head and neck cancer survival: a systematic review and meta-analysis. Oral Oncol 2012;48:1191–201.

   OpenUrlCrossRefPubMedWeb of Science
6. 6.↵
   1. Fakhry C,
   2. Westra WH,
   3. Li S,
   4. et al

   . Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 2008;100:261–9.

   OpenUrlAbstract/FREE Full Text
7. 7.↵
   1. Zaravinos A

   . An updated overview of HPV-associated head and neck carcinomas. Oncotarget 2014;5:3956–69.

   OpenUrlPubMed
8. 8.↵
   1. Gillison ML,
   2. Broutian T,
   3. Pickard RKL,
   4. et al

   . Prevalence of oral HPV infection in the United States, 2009–2010. JAMA 2012;307:693–703.

   OpenUrlCrossRefPubMedWeb of Science
9. 9.↵
   1. Gillison ML,
   2. D'Souza G,
   3. Westra W,
   4. et al

   . Distinct risk factor profiles for human papillomavirus type 16–positive and human papillomavirus type 16–negative head and neck cancers. J Natl Cancer Inst 2008;100:407–20.

   OpenUrlAbstract/FREE Full Text
10. 10.↵
    1. D'Souza G,
    2. Cullen K,
    3. Bowie J,
    4. Thorpe R,
    5. Fakhry C

    . Differences in oral sexual behaviors by gender, age, and race explain observed differences in prevalence of oral human papillomavirus infection. PLoS One 2014;9:e86023.

    OpenUrlCrossRefPubMed
11. 11.↵
    1. Gillison ML,
    2. Zhang Q,
    3. Jordan R,
    4. et al

    . Tobacco smoking and increased risk of death and progression for patients with p16-positive and p16-negative oropharyngeal cancer. J Clinl Oncol 2012;30:2102–11.

    OpenUrl
12. 12.↵
    1. Howard JD,
    2. Chung CH

    . Biology of human papillomavirus-related oropharyngeal cancer. Semin Radiat Oncol 2012;22:187–93.

    OpenUrlCrossRefPubMed
13. 13.↵
    1. Rogers SN,
    2. Vedpathak SV,
    3. Lowe D

    . Reasons for delayed presentation in oral and oropharyngeal cancer: the patients perspective. Br J Oral Maxillofac Surg 2011;49:349–53.

    OpenUrlCrossRefPubMed
14. 14.↵
    1. Jakscha,
    2. et al

    . The clinical impact of p16 status in fine-needle aspirates of cervical lymph node metastasis of head and neck squamous cell carcinomas. Eur Arch Otorhinolaryngol 2013;270:661–7.

    OpenUrlCrossRefPubMed
15. 15.↵
    1. Corey AS,
    2. Hudgins PA

    . Radiographic imaging of human papillomavirus related carcinomas of the oropharynx. Head Neck Pathol 2012;6:S25–40.

    OpenUrlCrossRefPubMed
16. 16.↵
    1. Broglie MA,
    2. Soltermann A,
    3. Haile SR,
    4. et al

    . Quality of life of oropharyngeal cancer patients with respect to treatment strategy and p16 positivity. Laryngoscope 2013;123:164–70.

    OpenUrlPubMed
17. 17.↵
    1. Pfister DG,
    2. Ang KK,
    3. Brizel DM,
    4. et al

    ; National Comprehensive Cancer Network. Head and neck cancers, version 2.2013. Featured updates to the NCCN guidelines. J Natl Compr Canc Netw 2013;11:917–23.

    OpenUrlAbstract/FREE Full Text
18. 18.↵
    1. Herrero R,
    2. Quint W,
    3. Hildesheim A

    . Reduced prevalence of oral human papillomavirus 4 years after bivalent hpv vaccination in a randomized clinical trial in Costa Rica. PLoS One 2013;8:e68329.

    OpenUrlCrossRefPubMed
19. 19.↵
    1. Chesson HW,
    2. Ekwueme DU,
    3. Saraiya M,
    4. Markowitz LE

    . Cost-effectiveness of Human Papillomavirus Vaccination in the United States. Emerging Infectious Diseases 2008; 14:244–251.

    OpenUrlPubMedWeb of Science
20. 20.↵
    1. Maciosek MV,
    2. Solberg LI,
    3. Coffield AB,
    4. Edwards NM,
    5. Goodman MJ

    . Influenza vaccination health impact and cost effectiveness among adults aged 50 to 64 and 65 and older. Am J Prev Med 2006;31:72–9.

    OpenUrlCrossRefPubMedWeb of Science